Rheumatoid arthritis (RA) is a chronic autoimmune disease in which skeletal joints become inflamed, causing pain, swelling and stiffness. RA can affect a person's ability to carry out everyday tasks. It is not known why rheumatoid arthritis develops, and there is no cure. Understanding of the disease has improved, however, and there are treatments that ease the pain and other symptoms, managing the disease.

Diya Lahiri, pharmaceutical industry analyst, said: "The world rheumatoid arthritis treatments market will benefit from the entry of new drugs this decade. There are prominent needs in the RA market, the most important being the development of drugs that are truly disease modifying rather than merely symptom managing. R&D efforts will help develop novel treatments that will not only benefit patients but also help researchers understand rheumatoid arthritis better."

Visiongain forecasts that the rheumatoid arthritis drug market will expand steadily to 2021. The future of the market is promising, with increasing demand for novel treatments such as biological drugs. The prospect of newer, more-effective drugs for RA, such as anti-TNF agents, will help this market to grow further. This new study adds to visiongain's wide range of analytical reports in healthcare and other industry areas.

To view sample pages please visit www.visiongain.com/Report/679/Rheumatoid-Arthritis-World-...

For an exec summary please email Sara Peerun
Email: sara.peerun@visiongainglobal.com
Tel: +44 0207 3366100

ENDS

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Visiongain Ltd
230 City Road
London
EC1V 2QY
United Kingdom

This release was published on openPR.